Literature DB >> 3987549

Haemodynamic effects of single-dose felodipine in normal man.

E Agner, M Rehling, J Trap-Jensen.   

Abstract

The haemodynamic effects of an oral solution of 15 mg felodipine were studied in 8 healthy males. Maximal plasma concentrations of felodipine were seen 30 to 40 minutes after administration, when significant decreases in diastolic and mean blood pressures were noted. Heart rate increased maximally by 45% after 30 minutes, accompanied by a 57% increase in cardiac output and 175% increase in forearm blood flow. Total peripheral resistance decreased by 40% and forearm vascular resistance by 66%. Apparent hepatic blood flow was unchanged.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3987549     DOI: 10.2165/00003495-198500292-00007

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  12 in total

1.  A study of the mechanism of the hemodynamic effects of hydralazine in man.

Authors:  B ABLAD
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1963

Review 2.  Vasodilator drugs in the treatment of hypertension.

Authors:  J Koch-Weser
Journal:  Arch Intern Med       Date:  1974-06

3.  The Minnesota impedance cardiograph- theory and applications.

Authors:  W G Kubicek; J Kottke; M U Ramos; R P Patterson; D A Witsoe; J W Labree; W Remole; T E Layman; H Schoening; J T Garamela
Journal:  Biomed Eng       Date:  1974-09

4.  Effect of age and high blood pressure on baroreflex sensitivity in man.

Authors:  B Gribbin; T G Pickering; P Sleight; R Peto
Journal:  Circ Res       Date:  1971-10       Impact factor: 17.367

5.  A strain gauge plethysmograph with electrical calibration.

Authors:  T Hallböök; B Månsson; R Nilsén
Journal:  Scand J Clin Lab Invest       Date:  1970-06       Impact factor: 1.713

6.  Comparison of acute effects of nifedipine in normotensive and hypertensive man.

Authors:  O Lederballe Pedersen; N J Christensen; K D Rämsch
Journal:  J Cardiovasc Pharmacol       Date:  1980 Jul-Aug       Impact factor: 3.105

7.  The systemic and coronary haemodynamic effects of felodipine in patients with coronary heart disease.

Authors:  A C Tweddel; G Johnsson; T H Pringle; R G Murray; I Hutton
Journal:  Eur Heart J       Date:  1983-10       Impact factor: 29.983

8.  Antihypertensive effect of cardiovascular Ca2+-antagonist in hypertensive patients in the absence and presence of beta-adrenergic blockade.

Authors:  K Aoki; S Kondo; A Mochizuki; T Yoshida; S Kato; K Kato; K Takikawa
Journal:  Am Heart J       Date:  1978-08       Impact factor: 4.749

9.  Felodipine--a new vasodilator, in addition to beta-receptor blockade in hypertension.

Authors:  D Elmfeldt; T Hedner
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

10.  Haemodynamic effects of a new vasodilator drug, felodipine, in healthy subjects.

Authors:  G Johnsson; G Murray; A Tweddel; I Hutton
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

View more
  5 in total

Review 1.  Calcium channel antagonists: Part VI: Clinical pharmacokinetics of first and second-generation agents.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1989-08       Impact factor: 3.727

Review 2.  Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  E Saltiel; A G Ellrodt; J P Monk; M S Langley
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

3.  Effects of felodipine and metoprolol on blood pressure, plasma renin, angiotensin II, aldosterone and catecholamines in hypertensive patients.

Authors:  P Lijnen; R Fagard; J Staessen; E Moerman; A De Schaepdryver; A Amery
Journal:  Drugs       Date:  1987       Impact factor: 9.546

4.  The acute renal haemodynamic and endocrine response to felodipine in normal man.

Authors:  D A Jenkins; K Craig; A D Cumming; M L Watson
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Antihypertensive and water and sodium balance effects of felodipine, a new vasodilating calcium antagonist, in hypertensive patients.

Authors:  G Leonetti; M Fruscio; L Terzoli; L Rupoli; R Gradnik; L Sampieri; C Cuspidi; L Boselli; G Bolla; A Zanchetti
Journal:  Drugs       Date:  1985       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.